Glycerophosphoinositol is Elevated in Blood Samples From CLN3 Δex7-8 pigs, Cln3 Δex7-8 Mice, and CLN3-Affected Individuals

Jon J Brudvig; Vicki J Swier; Tyler B Johnson; Jacob C Cain; Melissa Pratt; Mitch Rechtzigel; Hannah Leppert; An N Dang Do; Forbes D Porter; Jill M Weimer

doi:10.1177/11772719221107765

Glycerophosphoinositol is Elevated in Blood Samples From CLN3 ^Δex7-8 pigs, Cln3 ^Δex7-8 Mice, and CLN3-Affected Individuals

Biomark Insights. 2022 Jun 19:17:11772719221107765. doi: 10.1177/11772719221107765. eCollection 2022.

Authors

Jon J Brudvig^{1

2

3}, Vicki J Swier¹, Tyler B Johnson^{1

3}, Jacob C Cain^{1

3}, Melissa Pratt¹, Mitch Rechtzigel¹, Hannah Leppert¹, An N Dang Do⁴, Forbes D Porter⁴, Jill M Weimer^{1

2

3}

Affiliations

¹ Pediatrics & Rare Diseases, Sanford Research, Sioux Falls, SD, USA.
² Pediatrics, University of South Dakota Sanford School of Medicine, Vermillion, SD, USA.
³ Discovery Science, Amicus Therapeutics, Philadelphia, PA, USA.
⁴ Division of Translational Medicine, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, MD, USA.

Abstract

Introduction: CLN3 Batten disease is a rare pediatric neurodegenerative lysosomal disorder caused by biallelic disease-associated variants in CLN3. Despite decades of intense research, specific biofluid biomarkers of disease status have not been reported, hindering clinical development of therapies. Thus, we sought to determine whether individuals with CLN3 Batten disease have elevated levels of specific metabolites in blood.

Methods: We performed an exhaustive metabolomic screen using serum samples from a novel minipig model of CLN3 Batten disease and validated findings in CLN3 pig serum and CSF and Cln3 mouse serum. We further validate biomarker candidates with a retrospective analysis of plasma and CSF samples collected from participants in a natural history study. Plasma samples were evaluated from 22 phenotyped individuals with CLN3 disease, 15 heterozygous carriers, and 6 non-affected non-carriers (NANC).

Results: CLN3 pig serum samples from 4 ages exhibited large elevations in 4 glycerophosphodiester species: glycerophosphoinositol (GPI), glycerophosphoethanolamine (GPE), glycerophosphocholine (GPC), and glycerophosphoserine (GPS). GPI and GPE exhibited the largest elevations, with similar elevations found in CLN3 pig CSF and Cln3 mouse serum. In plasma samples from individuals with CLN3 disease, glycerophosphoethanolamine and glycerophosphoinositol were significantly elevated with glycerophosphoinositol exhibiting the clearest separation (mean 0.1338 vs 0.04401 nmol/mL for non-affected non-carriers). Glycerophosphoinositol demonstrated excellent sensitivity and specificity as a biomarker, with a receiver operating characteristic area under the curve of 0.9848 (P = .0003).

Conclusions: GPE and GPI could have utility as biomarkers of CLN3 disease status. GPI, in particular, shows consistent elevations across a diverse cohort of individuals with CLN3. This raises the potential to use these biomarkers as a blood-based diagnostic test or as an efficacy measure for disease-modifying therapies.

Keywords: Biomarkers; lipid metabolism; metabolomics; neuronal ceroid-lipofuscinoses.